Cargando…
Delivery of nucleic acid therapeutics for cancer immunotherapy
Cancer immunotherapy has shown great potential as witnessed by an increasing number of immuno-oncology drug approvals in the past few years. Meanwhile, the field of nucleic acid therapeutics has made significant advancement. Nucleic acid therapeutics, such as plasmids, antisense oligonucleotides (AS...
Autores principales: | Zhou, Shurong, Chen, Wenjie, Cole, Janet, Zhu, Guizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320672/ https://www.ncbi.nlm.nih.gov/pubmed/34337382 http://dx.doi.org/10.1016/j.medidd.2020.100023 |
Ejemplares similares
-
Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy
por: Zhou, Shurong, et al.
Publicado: (2023) -
Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy
por: Baker, Abu, et al.
Publicado: (2023) -
ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis
por: Hu, Lujun, et al.
Publicado: (2020) -
Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery
por: Boisguérin, Prisca, et al.
Publicado: (2021) -
Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy
por: Zhang, Chi, et al.
Publicado: (2022)